Answers are grounded in this paper and cite their sources.
Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. (Funded by Eli Lilly; GZGI ClinicalTrials.gov number, NCT05051579.).
No takes yet. Share an insight, caveat, or question.
Wharton et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: